Summit Therapeutics Inc (SMMT)
19.00
+0.58
(+3.15%)
USD |
NASDAQ |
Nov 22, 16:00
19.02
+0.02
(+0.11%)
After-Hours: 20:00
Summit Therapeutics Net Income (Quarterly): -56.25M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -56.25M |
| June 30, 2024 | -60.38M |
| March 31, 2024 | -43.47M |
| December 31, 2023 | -36.57M |
| September 30, 2023 | -21.27M |
| June 30, 2023 | -14.72M |
| March 31, 2023 | -542.38M |
| December 31, 2022 | -19.23M |
| September 30, 2022 | -21.38M |
| June 30, 2022 | -16.77M |
| March 31, 2022 | -21.40M |
| December 31, 2021 | -27.10M |
| September 30, 2021 | -19.60M |
| June 30, 2021 | -24.42M |
| March 31, 2021 | -17.49M |
| December 31, 2020 | -13.54M |
| September 30, 2020 | -17.74M |
| June 30, 2020 | -15.28M |
| March 31, 2020 | -6.134M |
| October 31, 2019 | -9.069M |
| July 31, 2019 | -6.274M |
| April 30, 2019 | -5.205M |
| Date | Value |
|---|---|
| January 31, 2019 | -5.215M |
| October 31, 2018 | -10.34M |
| July 31, 2018 | 34.98M |
| April 30, 2018 | -8.044M |
| January 31, 2018 | -16.77M |
| October 31, 2017 | -1.143M |
| July 31, 2017 | -4.312M |
| April 30, 2017 | -6.156M |
| January 31, 2017 | -6.630M |
| October 31, 2016 | -5.595M |
| July 31, 2016 | -8.494M |
| April 30, 2016 | -7.943M |
| January 31, 2016 | -8.598M |
| October 31, 2015 | -8.170M |
| July 31, 2015 | -6.292M |
| April 30, 2015 | -5.192M |
| January 31, 2015 | -3.791M |
| October 31, 2014 | -3.914M |
| July 31, 2014 | -5.549M |
| April 30, 2014 | -4.415M |
| January 31, 2014 | -3.934M |
| October 31, 2013 | -2.857M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-542.38M
Minimum
Mar 2023
-6.134M
Maximum
Mar 2020
-52.37M
Average
-21.27M
Median
Sep 2023
Net Income (Quarterly) Benchmarks
| Merck & Co Inc | 3.157B |
| Terns Pharmaceuticals Inc | -21.94M |
| Instil Bio Inc | -23.02M |
| Viking Therapeutics Inc | -24.94M |
| Moderna Inc | 13.00M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 58.38M |
| EPS Diluted (Quarterly) | -0.08 |
| Enterprise Value | 13.55B |
| Earnings Yield | -1.26% |
| Normalized Earnings Yield | -3.165 |